It looks like your message got cut off! Could you finish your thought? What would you like help with?

Reading Document

Medical Text Search

myocardial infarction STEMI NSTEMI pathophysiology diagnosis management

Medical Text Search

acute MI ECG findings troponin biomarkers treatment reperfusion

Medical Image Search

myocardial infarction ECG ST elevation coronary anatomy

GradeResponse

Myocardial Infarction (MI)

Overview

A myocardial infarction occurs when prolonged ischemia leads to irreversible cardiomyocyte death, most commonly due to rupture of an atherosclerotic plaque with superimposed thrombosis occluding a coronary artery. The umbrella term Acute Coronary Syndrome (ACS) encompasses:

Syndrome	ECG	Biomarkers
Unstable Angina (UA)	No persistent STE	Negative
NSTEMI	No persistent STE	Positive (elevated troponin)
STEMI	Persistent ST elevation	Positive

Epidemiologically, NSTEMIs now outnumber STEMIs (Harrison's, p. 7562).

Pathophysiology

Atherosclerotic plaque forms in coronary artery wall (lipid core + fibrous cap)
Plaque rupture or erosion exposes subendothelial collagen → platelet activation + aggregation
Thrombus formation → partial (NSTEMI/UA) or complete (STEMI) occlusion
Ischemia → injury → infarction cascade if flow not restored
Myocyte necrosis releases intracellular proteins (troponin, CK-MB) into bloodstream

Clinical Presentation

Classic: crushing/pressure-like chest pain radiating to left arm, jaw, or back; diaphoresis, nausea, dyspnea
Atypical (women, elderly, diabetics): fatigue, epigastric discomfort, syncope, no chest pain ("silent MI")
Killip classification grades hemodynamic severity (I–IV)

Diagnosis

ECG (pivotal triage tool — Harrison's, p. 7562)

The 12-lead ECG is the centerpiece of ACS decision-making:

Finding	Significance
ST elevation ≥1 mm in ≥2 contiguous limb leads	STEMI
ST elevation ≥2 mm in ≥2 contiguous precordial leads	STEMI
New LBBB	STEMI-equivalent
ST depression, T-wave inversions	NSTEMI/UA
Hyperacute T-waves	Early/hyperacute MI

Beyond traditional STE, recognized patterns of Acute Coronary Occlusion MI (ACOMI) include subtle findings in posterior, inferior, high lateral, and right ventricular walls — requiring supplemental leads (V7–V9, V3R/V4R) to detect (Diagnosing and Managing ACS, p. 21).

High lateral MI can present with STE in non-contiguous leads (I, aVL) due to occlusion of the first diagonal branch of the LAD — the "South African flag sign."

Multi-panel composite: (a) STEMI with high lateral ST elevation in leads I and aVL with reciprocal inferior depression; (b) ECG after ST resolution; (c–e) coronary angiograms showing SCAD with dissection flap in distal LM/proximal LAD, and healing at 6 days.

Cardiac Biomarkers

High-sensitivity Troponin I/T — gold standard; rises within 1–3 hours, peaks at 12–24 h
CK-MB — useful for reinfarction (shorter half-life)
Serial troponins at 0/1h or 0/3h for rapid rule-in/rule-out protocols

Imaging

Echocardiography: regional wall motion abnormalities, EF assessment, mechanical complications
Coronary angiography: defines anatomy, guides PCI
Cardiac MRI: viability, infarct size, microvascular obstruction

Management

STEMI — Time is Myocardium

Goal: door-to-balloon ≤90 min (PCI-capable center) or door-to-needle ≤30 min (fibrinolysis)

Strategy	Indication
Primary PCI	Preferred if available within 120 min of first medical contact
Fibrinolysis (tPA, tenecteplase)	No PCI available within 120 min; administer within 12h of symptom onset
CABG	Left main disease, failed PCI, mechanical complications

NSTEMI/UA — Risk-Stratify First

TIMI or GRACE score to guide invasive vs. conservative strategy
Early invasive (<24h): high-risk features (elevated troponin, dynamic ECG changes, hemodynamic instability)
Conservative: low-risk patients

Pharmacotherapy

Drug Class	Agents	Role
Antiplatelet	Aspirin + P2Y12 inhibitor (ticagrelor, prasugrel, clopidogrel)	Dual antiplatelet therapy (DAPT)
Anticoagulant	Heparin (UFH/LMWH), bivalirudin, fondaparinux	Acute phase
Beta-blocker	Metoprolol, carvedilol	Reduce myocardial oxygen demand, prevent arrhythmia
ACE inhibitor/ARB	Ramipril, lisinopril	Reduce remodeling; start within 24h if EF reduced
Statin	High-intensity (atorvastatin 40–80 mg)	Plaque stabilization, mortality benefit
Nitroglycerin	SL or IV	Pain relief, preload reduction
Morphine	IV	Use cautiously (may delay P2Y12 absorption)

Supplemental Oxygen

Administer only if SpO₂ <90%; routine O₂ in normoxic patients may be harmful.

Complications

Time	Complication
Early (<24h)	VF, complete heart block, cardiogenic shock
1–3 days	Free wall rupture, VSD, papillary muscle rupture (acute MR)
Days–weeks	Pericarditis (Dressler's syndrome), LV thrombus, heart failure
Long-term	LV remodeling, chronic heart failure, recurrent MI

Prognosis

In-hospital mortality for STEMI ~5–10% with modern reperfusion; significantly higher with cardiogenic shock (~50%)
Key predictors of poor outcome: anterior location, delayed reperfusion, reduced EF, age, comorbidities
Secondary prevention (DAPT, statin, beta-blocker, ACEI, cardiac rehab) substantially reduces recurrence

Sources: Harrison's Principles of Internal Medicine, 21st Ed. (p. 7562); Diagnosing and Managing Acute Coronary Syndromes (p. 21)

This is a shared conversation. Sign in to Orris to start your own chat.